denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Session: 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster II
Hematology Disease Topics & Pathways:
Clinical Practice (Health Services and Quality)
Lower-risk myelodysplastic syndromes (LR-MDS) are characterized by anemia in the majority of patients (pts), with more than half of pts becoming red blood cell (RBC) transfusion dependent. A goal of therapy is to alleviate cytopenia and its related complications. We assessed differences in clinical information used to guide LR-MDS treatment decision-making and barriers to treatment decisions between community and academic hematology/oncology providers in a nationwide survey.
Methods
During April 2024, a survey was sent twice two days apart to 29,192 hematology/oncology healthcare providers (HCPs), with survey access denied upon reaching the pre-defined goal (1% completion rate). Means and ranges are presented for summary statistics, and comparisons between groups were conducted using Chi-square statistics, with p-values <.05 denoting significance.
Results
Among 133 HCPs, the median age was 50 years (range, 30-89), 20% Asian, 14% Hispanic, 12% Black, and 50% White. Most (67%) were physicians, 17% nurses, 5% nurse practitioners, and 8% pharmacists. Half practiced in a community setting, 37% in an academic setting, and 12% in an outpatient infusion center. Access to pathology and genetic facilities differed by practice setting, with 86% and 44% of academic HCPs but only 23% and 15% of community HCPs having a pathologist on staff or in-house genomics, respectively (both p< .001). Academic HCPs identified considering the patient’s molecular and cytogenetic profile (48%) and uncertainty about who the “right” pts for new therapies are (42%) as the biggest barriers to integrating frontline LR-MDS therapies, while community HCPs identified difficulty translating the latest guidelines and clinical data into practice (65%) and lack of expertise in the administration nuances and adverse event management for novel therapies (64%). Practice setting impacted perceived pts challenges, with academic HCPs reporting their pts’ top challenges to considering frontline therapy as affording the cost of medication/ensuring insurance coverage (52%) and hesitation/uncertainty on initiating treatment (42%), contrasting to community HCPs reporting arranging caregiver support for transportation to/from appointments and/or disease management at home (71%) and living too far from treatment center for potential infusions and/or follow-up care (50%).
There were no significant differences between academic and community HCPs who reported treating LR-MDS pts in the frontline setting with erythropoiesis-stimulating agents, luspatercept, lenalidomide, hypomethylating agents, or immunosuppressive therapy; however, more academic providers reported use of regular RBC transfusions compared to community providers (33% vs 23%, p=.179), possibly indicating more advanced MDS. More academic than community HCPs reported using current transfusion requirements (82% vs 70%, p=.130) and hemoglobin (Hb) levels (40% vs 15%, p=.002) to inform the decision to start non-supportive care therapies. Of the HCPs who used transfusion requirements to inform treatment initiation, more community HCPs selected requiring 1 unit of blood every 2 months than academic HCPs (64% vs 10%, p<.001), with more academic HCPs (28% vs 11% of community HCPs, p=.016) indicating 2 units of blood per month. Similarly, for those who use Hb level to inform treatment initiation, more academic than community HCPs (45% vs 26%, p=.023) indicated that a Hb < 8 g/dL would warrant treatment initiation, while more community HCPs (38% vs 18%, p=.017) indicated a Hb of < 9 g/dL.
Full findings from the survey, including sub-analyses by regional census data, will be presented.
Conclusions
Findings from this nationwide hematology/oncology provider survey revealed differences in factors considered for treatment initiation and barriers to treatment choice between academic and community HCPs who care for pts with LR-MDS. Of note, academic and community HCPs differed in their use of threshold Hb level or transfusion requirements to initiate treatment. Pts may be started on regular RBC transfusions, growth factors, or disease-modifying therapies at different timepoints of their disease depending on the practice setting.
Study Sponsor Statement
The study reported in this abstract was funded by an educational grant from Bristol Myers Squibb. The grantor had no role in the study design, execution, analysis, or reporting.
Disclosures: Sekeres: Schroedinger: Membership on an entity's Board of Directors or advisory committees; Kurome: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees, Research Funding. Watts: Immune Systems Key: Research Funding; Rafael Pharma: Consultancy; Reven Pharma: Consultancy; Daiichi Sankyo: Consultancy; Takeda: Research Funding; Celgene/BMS: Consultancy; Aptose: Consultancy, Membership on an entity's Board of Directors or advisory committees; Incyte: Research Funding; Servier: Consultancy, Membership on an entity's Board of Directors or advisory committees; Rigel: Consultancy, Other: safety monitoring or advisory boards, Research Funding. Bradley: Geron Corporation: Membership on an entity's Board of Directors or advisory committees; Gilead: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Sallman: Abbvie: Consultancy; Agios: Consultancy; Axiom: Consultancy; Gilead: Consultancy; Celyad: Consultancy; Froghorn: Consultancy; Incyte: Consultancy; Intellisphere, LLC: Consultancy; Johnson & Johnson: Consultancy; Kite: Consultancy, Membership on an entity's Board of Directors or advisory committees; Magenta Therapeutics: Consultancy, Membership on an entity's Board of Directors or advisory committees; NextTech: Consultancy; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees; AvenCell: Membership on an entity's Board of Directors or advisory committees; Astellas: Membership on an entity's Board of Directors or advisory committees; BlueBird Bio: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Dark Blue Therapeutics: Membership on an entity's Board of Directors or advisory committees; Intellia: Membership on an entity's Board of Directors or advisory committees; Jasper Therapeutics: Membership on an entity's Board of Directors or advisory committees; NKARTA: Membership on an entity's Board of Directors or advisory committees; Orbital Therapeutics: Membership on an entity's Board of Directors or advisory committees; Rigel Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Shattuck Labs: Membership on an entity's Board of Directors or advisory committees; Servier: Membership on an entity's Board of Directors or advisory committees; Syndax: Membership on an entity's Board of Directors or advisory committees; Syros: Membership on an entity's Board of Directors or advisory committees; Apera: Research Funding; Jazz: Research Funding. Komrokji: Celgene/BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Sobi: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; DSI: Consultancy, Membership on an entity's Board of Directors or advisory committees; Servio: Membership on an entity's Board of Directors or advisory committees; CTI biopharma: Membership on an entity's Board of Directors or advisory committees; BMS: Research Funding; Janssen: Consultancy; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; Keros: Membership on an entity's Board of Directors or advisory committees; Jazz Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Servio: Honoraria; DSI: Honoraria, Membership on an entity's Board of Directors or advisory committees; Taiho: Membership on an entity's Board of Directors or advisory committees; Servier: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Geron: Consultancy, Membership on an entity's Board of Directors or advisory committees; PharmaEssentia: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Rigel: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; Genentech: Consultancy; Sumitomo Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees.
See more of: Oral and Poster Abstracts